A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis - 14/06/22
Abstract |
Background |
Vunakizumab (SHR-1314) is a novel interleukin 17A monoclonal antibody that has shown preliminary efficacy and tolerability in phase I trials.
Objective |
To evaluate the efficacy and safety of vunakizumab in moderate-to-severe plaque psoriasis.
Methods |
In this 36-week, multicenter, double-blinded, phase II study (NCT03463187), 187 eligible patients with moderate-to-severe plaque psoriasis were randomized 1:1:1:1:1 to receive vunakizumab (40, 80, 160, or 240 mg) or placebo subcutaneously, every 4 weeks, until week 12 (2 more drug administrations for the vunakizumab groups on weeks 16 and 20). The primary end point was at least 75% improvement in the Psoriasis Area and Severity Index at week 12.
Results |
At week 12, there were significantly greater proportions of responders with at least 75% improvement in the Psoriasis Area and Severity Index in all vunakizumab groups compared to placebo (40, 80, 160, and 240 mg: 56.8%, 65.8%, 81.6%, and 86.5%, respectively, vs 5.4%; P < .001 for all); the proportions of patients achieving Physician's Global Assessment responses of 0 or 1 were also higher with vunakizumab (45.9%, 47.4%, 60.5%, and 73.0%, respectively, vs 8.1%). No unexpected adverse effects were observed.
Limitations |
The study was relatively short in duration and included no active control.
Conclusion |
Vunakizumab showed promising efficacy for moderate-to-severe plaque psoriasis, with good tolerability, warranting further investigation in larger and longer-term studies.
Il testo completo di questo articolo è disponibile in PDF.Key words : anti–IL-17A, biologics, clinical trial, plaque psoriasis, psoriasis area and severity index, quality of life
Abbreviations used : ADA, AE, BSA, DLQI, IL, NAB, PASI, PGA
Mappa
| Drs Zhang, Yan, and Diao contributed equally to this article. |
|
| Funding sources: Supported by Jiangsu Hengrui Pharmaceuticals Co, Ltd (formerly Jiangsu Hengrui Medicine Co, Ltd). |
|
| IRB approval status: Reviewed and approved by all trial centers (Huashan Hospital Affiliated to Fudan University, Shanghai, China; Peking University Third Hospital, Beijing, China; Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China; The First Affiliated Hospital of Anhui Medical University, Hefei, China; Xiangya Hospital, Central South University, Changsha, China; Renmin Hospital of Wuhan University, Hubei General Hospital, Wuhan, China; Changhai Hospital of Shanghai, Shanghai, China; Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China; The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China; The 1st Hospital of China Medical University, Shenyang, China; Sinclair Dermatology, East Melbourne, Australia; Veracity Clinical Research Pty Ltd, Woolloongabba, Australia; Westmead Hospital, Westmead, Australia; St George Dermatology and Skin Cancer Centre, Kogarah, Australia; Revival Research, Doral, Florida; Elite Clinical Studies, LLC, Phoenix, Arizona; Anaheim Clinical Trials, Anaheim, California; Indago Research and Health Center-Emergency Medicine, Hialeah, Florida; Great Lakes Clinical Trials LLC, Chicago, Illinois; Clinical Partners, LLC, Johnston, Rhode Island; Center for Clinical Studies, Houston, Texas; Center for Clinical Studies, Webster, Texas). |
|
| Reprints not available from the authors. |
Vol 87 - N° 1
P. 95-102 - luglio 2022 Ritorno al numero
Articolo precedente
- Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study
- Emily S. Ruiz, Kylee J.B. Kus, Timothy D. Smile, Fadi Murad, Guohai Zhou, Evelyn O. Ilori, Jonathan D. Schoenfeld, Danielle N. Margalit, Roy B. Tishler, Allison T. Vidimos, Shlomo A. Koyfman, Chrysalyne D. Schmults
- Comparing the efficacy and safety of laser treatments in tattoo removal: A systematic review
- Pooja Gurnani, Natalie Williams, Ghadah AL-Hetheli, Olivia Chukwuma, Rebecca Roth, Francisco Fajardo, Keyvan Nouri
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?